<?xml version="1.0" encoding="UTF-8"?>
<p id="par0250">In Brazil, due to the lack of specific medications, the Ministry of Health has authorized the use of CQ or HCQ as an adjunct therapy in the treatment of severe forms of COVID-19 in hospitalized patients [
 <xref rid="bib0640" ref-type="bibr">128</xref>]. Even CQ being considered as an option to SARS-CoV-2 treatment, due to its low cost, easy accessibility and previous studies of its effects in the malaria treatment [
 <xref rid="bib0515" ref-type="bibr">103</xref>], the capacity to be ototoxic and retinotoxic in the fetal phase for individuals exposed to chloroquine raises concerns about its use [
 <xref rid="bib0645" ref-type="bibr">129</xref>,
 <xref rid="bib0650" ref-type="bibr">130</xref>]. In contrast, many studies suggest that there is no increase in congenital malformations associated with the use of HCQ. Evidences also support the compatibility of HCQ with breastfeeding [
 <xref rid="bib0655" ref-type="bibr">131</xref>] and it is also important to note that for rheumatological diseases it is allowed and recommended the HCQ use during pregnancy [
 <xref rid="bib0660" ref-type="bibr">132</xref>].
</p>
